SI
ACAD icon

Sofinnova Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Sofinnova Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-500,000
Closed -$8.3M – 64
2025
Q1 		$8.3M Buy
+500,000
New +$9.08M 0.54% 42
2021
Q3 		– Sell
-100,000
Closed -$2.44M – 71
2021
Q2 		$2.44M Buy
+100,000
New +$2.26M 0.14% 61

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sofinnova Investments's ACAD Position: Q2 2026 in Review

Sofinnova Investments sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 78,551 shares — an estimated $1.75M sold.

Sofinnova Investments first reported a position in ACAD in Q2 2019 and held it in 6 quarters. The position peaked at $8.8M in Q4 2020. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Sofinnova Investments reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sofinnova Investments sold 78,551 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.75M.
  • Sofinnova Investments first reported a position in Acadia Pharmaceuticals in Q2 2019 and held it in 6 quarters.
  • Sofinnova Investments's Acadia Pharmaceuticals position peaked at $8.8M in Q4 2020.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.